HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. BOLT | 0.00 |
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:
BOLT) with a Buy and maintains $7 price target.
